Literature DB >> 29721372

Protective effects against tumors and infection by interleukin-27 through promotion of expansion and differentiation of hematopoietic stem cells into myeloid progenitors.

Naoko Orii1, Izuru Mizoguchi1, Yukino Chiba1, Hideaki Hasegawa1, Mio Ohashi1, Mingli Xu1, Taro Nagai2, Nakaba Ochiai1, Yuki Mochizuki1, Toshiyuki Owaki1, Takayuki Yoshimoto1.   

Abstract

Interleukin (IL)-27 is a multifunctional cytokine that belongs to the IL-6/IL-12 family and has potent antitumor activity through various mechanisms. Our novel findings indicate that IL-27 directly acts on hematopoietic stem cells and promotes their expansion and differentiation into myeloid progenitors to control infection and to eradicate tumors.

Entities:  

Keywords:  IL-27; antitumor activity; emergency myelopoiesis; hematopoietic stem cells; myeloid progenitors

Year:  2018        PMID： 29721372      PMCID： PMC5927478          DOI： 10.1080/2162402X.2017.1421892

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

Review 1.  The immunobiology of interleukin-27.

Authors:  Hiroki Yoshida; Christopher A Hunter
Journal:  Annu Rev Immunol       Date:  2015       Impact factor: 28.527

2.  Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages.

Authors:  Yukino Chiba; Izuru Mizoguchi; Junichi Furusawa; Hideaki Hasegawa; Mio Ohashi; Mingli Xu; Toshiyuki Owaki; Takayuki Yoshimoto
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

3.  A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection.

Authors:  T Yoneto; S Waki; T Takai; Y Iwakura; J Mizuguchi; H Nariuchi; T Yoshimoto
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

4.  IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation.

Authors:  Tomohiro Yoshimoto; Takayuki Yoshimoto; Koubun Yasuda; Junichiro Mizuguchi; Kenji Nakanishi
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

5.  Potent antitumor activity of interleukin-27.

Authors:  Masayuki Hisada; Sadahiro Kamiya; Koji Fujita; Maria Laura Belladonna; Tatuya Aoki; Yasuhisa Koyanagi; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

6.  Therapeutic potential of interleukin-27 against cancers in preclinical mouse models.

Authors:  Izuru Mizoguchi; Yukino Chiba; Jun-Ichi Furusawa; Mingli Xu; Ren Tsunoda; Kaname Higuchi; Takayuki Yoshimoto
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

7.  Interleukin-27 directly induces differentiation in hematopoietic stem cells.

Authors:  Jun Seita; Masayuki Asakawa; Jun Ooehara; Shin-Ichiro Takayanagi; Yohei Morita; Nobukazu Watanabe; Koji Fujita; Motoshige Kudo; Junichiro Mizuguchi; Hideo Ema; Hiromitsu Nakauchi; Takayuki Yoshimoto
Journal:  Blood       Date:  2007-11-27       Impact factor: 22.113

Review 8.  Potential clinical application of interleukin-27 as an antitumor agent.

Authors:  Takayuki Yoshimoto; Yukino Chiba; Jun-Ichi Furusawa; Mingli Xu; Ren Tsunoda; Kaname Higuchi; Izuru Mizoguchi
Journal:  Cancer Sci       Date:  2015-08-06       Impact factor: 6.716

9.  Promotion of Expansion and Differentiation of Hematopoietic Stem Cells by Interleukin-27 into Myeloid Progenitors to Control Infection in Emergency Myelopoiesis.

Authors:  Jun-ichi Furusawa; Izuru Mizoguchi; Yukino Chiba; Masayuki Hisada; Fumie Kobayashi; Hiroki Yoshida; Susumu Nakae; Akihiko Tsuchida; Tetsuya Matsumoto; Hideo Ema; Junichiro Mizuguchi; Takayuki Yoshimoto
Journal:  PLoS Pathog       Date:  2016-03-18       Impact factor: 6.823
  9 in total
  1 in total

Review 1.  Immunoregulatory Functions of the IL-12 Family of Cytokines in Antiviral Systems.

Authors:  Yifei Guo; Wei Cao; Ying Zhu
Journal:  Viruses       Date:  2019-08-22       Impact factor: 5.048
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.